All News

PsA.Hands_.jpg

Updates on Psoriatic Arthritis at ACR 2018

d Philip Gardiner

I think 2018 was the year that belonged to psoriatic arthritis (although some may argue in favor of immune conditions induced by Checkpoint inhibitors). Many years ago the late Professor Verna Wright in Leeds (UK) was a lone voice for many years describing the clinical subtypes of Psoriatic arthritis as something distinctive from rheumatoid arthritis. For a long time we thought that the treatments for PsA were just the same as RA since we were treating the same problem of synovitis.

Read Article
.@BrennanSpiegel Digital sensors are now available for multiple organ systems #ACR18 @RheumNow https://t.co/RFMA9eArbt
Suleman Bhana, MD DrBhana ( View Tweet)
Numbers just released - 15,000 attendees at #ACR18 from 106 countries

Felicity Nelson frogsandstars ( View Tweet)

Well done to our outstanding former registrar Bess Leonardo for her excellent work that was presented at #ACR18 today (poster 2353), looking at how RA patients access information about MTX. https://t.co/PF0BNQpdKl
ǝlʇʇıɥʍ ɯɐs samwhittle ( View Tweet)
2018 Great Debate examines questions about hydroxychloroquine dosing guidelines https://t.co/ltOnUmtrzw

Links:

ǝlʇʇıɥʍ ɯɐs samwhittle ( View Tweet)

This enjoyable #ACR18 #fibromyalgia session is an appropriate time for a couple of periodic reminders: 1. Pain is an output of the brain (not an input) 2. Fibromyalgia is best conceptualised as a *description*, not an *explanation*

ǝlʇʇıɥʍ ɯɐs samwhittle ( View Tweet)

#Vasculitis oral abstract session at #ACR18: back to back abstracts on use of #leflunomide for #GCA and #PMR. Promising results on efficacy and #steroid sparing effect. Could it become a standard alternative when tocilizumab contraindicated or not available?

Angelo Gaffo ALGaffoRheumMD ( View Tweet)

#ACR18 #2923: Persistence of bone marrow oedema within the same SIJ quadrant associated with structural damage at 5 years in patients with early axial SpA. @RheumNow

ǝlʇʇıɥʍ ɯɐs samwhittle ( View Tweet)

#ACR18 #2924 - Great work by the always-impressive Sofia Ramiro using DESIR data in early AxSpA. Early progression (2-5yrs) of syndesmophytes predicted by baseline inflammation (MRI) and damage (XR). @RheumNow https://t.co/D9aGXFUtcd
ǝlʇʇıɥʍ ɯɐs samwhittle ( View Tweet)
#ACR18 #2952 - Validation of a clinical risk score for NSAID toxicity. Most patients fall into intermediate category, but 5% low risk, 25% high risk: probably useful in clinic if externally validated & calculator were available at point of care. @RheumNow https://t.co/DjdaYLwuX3
ǝlʇʇıɥʍ ɯɐs samwhittle ( View Tweet)
#ACR18 #2954 Brave presentation from Dr Jin under pressure from a feisty Jim O’Dell in the audience. Analysis of US claims database regarding combo Rx for RA. Only 3% of MTX combo is triple therapy (cf MTX+TNFi). No evidence for change over time. @RheumNow

ǝlʇʇıɥʍ ɯɐs samwhittle ( View Tweet)

#ACR18 #2956 Interesting UK CPRD data on opioid prescribing presented by @MeghnaJani - UK prescribers seem to be getting the message about opioids, but work still to be done (esp regarding use of strong opioids, with are hard to transition off). @RheumNow https://t.co/LwyVVVfw8i
ǝlʇʇıɥʍ ɯɐs samwhittle ( View Tweet)
RheumNow expanded twitter coverage of the ACR 2018 Annual meeting sponsored in part by Novartis. All content chosen and distributed by RheumNow and its faculty.

Dr. John Cush RheumNow ( View Tweet)

Patients with elevated IL-6 baseline levels had greater response to sarilumab compared with MTX or adalimumab. #L08 https://t.co/uxMOSD2B1E @RheumNow #ACR18

Links:

Dr. Rachel Tate uptoTate ( View Tweet)

Possible efficacy with LEF/HCQ in primary SS. #L10 https://t.co/1BKglr3JSF @RheumNow #ACR18

Links:

Dr. Rachel Tate uptoTate ( View Tweet)

RheumNow expanded twitter coverage of the ACR 2018 Annual meeting sponsored in part by Horizon Pharma. All content chosen and distributed by RheumNow and its faculty.

Dr. John Cush RheumNow ( View Tweet)

IXE efficacious in r-axSpA at Week 16 in TNF failure pts. #L12 https://t.co/MCpXDj9Z2o @RheumNow #ACR18

Links:

Dr. Rachel Tate uptoTate ( View Tweet)

SEC shows efficacy in AS over 5 years. #L13 https://t.co/JQFdYlA3ku @RheumNow #ACR18

Links:

Dr. Rachel Tate uptoTate ( View Tweet)

US can be used to reliably identify structural and inflammatory changes in knee OA – often earlier or better than plain radiography. https://t.co/MSp2QlqSFP @RheumNow #ACR18 #2909

Links:

Dr. Rachel Tate uptoTate ( View Tweet)

RheumNow expanded twitter coverage of the ACR 2018 Annual meeting sponsored in part by Eli Lilly and Company. All content chosen and distributed by RheumNow and its faculty.

Dr. John Cush RheumNow ( View Tweet)

×